Vivimed Labs Limited · NSE:VIVIMEDLAB
Vivimed Labs — Q1 FY2016 Earnings Presentation
18 slides from Vivimed Labs's earnings presentation, Aug 14, 2015
Slide 1: Vivimed Labs Limited Q1 FY2016 Earnings Presentation
Vivimed Labs Limited Q1 FY2016 Earnings Presentation August 14, 2015 © Vivimed Labs Ltd 2010 All rights reserved 1 www.vivimedlabs.com
Slide 2: Important Notice
Important Notice No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after
Slide 3: Vivimed Group Overview
Vivimed Group Overview A leading international brand in the Specialty Chemicals and Pharmaceuticals with global presence R&D Centres: Manufacturing Team Size 5 facilities +2,300 People R&D Team: 170+ personnel 12 (4 USFDA) 71.1% 28.9% Healthcare Specialty Chemicals • API • Personal Care • Contract F
Slide 4: Vivimed Group Overview
Vivimed Group Overview Preferred supplier to the leading global brands 4
Slide 5: Consolidated Financial Performance
Consolidated Financial Performance Performance Highlights: Q1 FY2016 vs. Q1 FY2015 Q1 FY2016 Revenue Breakup 3.8% Net Sales of Rs. 3,330 million 10.8% 71.1% 14.3% EBITDA of Rs. 672 million (up 15.8%) o EBITDA margin of 20.2%; significant improvement of 440 bps Net Profit of Rs. 242 million (up
Slide 6: Financial Performance
Financial Performance Consolidated Financials Q1 y-o-y Q4 q-o-q Full Year y-o-y Growth Growth Growth (Rs. million) FY2016 FY2015 FY2015 FY2015 FY2014 (%) (%) (%) Net Sales 3,330 3,678 (9.5)% 3,567 (6.7)% 13,860 13,590 2.0% EBITDA 672 581 15.8% 526 27.7% 2,228 2,133 4.4% Margin (%) 20.2% 15.8% 14.8%
Slide 7: Financial Performance: Management Perspectives
Financial Performance Management Perspectives • Revenues declined 9.5% y-o-y to Rs. 3,330 million primarily due to decline in healthcare revenues as a result of unfavourable variation in the EURO-INR equation. Despite strategic reduction in volumes of low margin products, the Speciality Chemicals bu
Slide 8: Segment Highlights
Segment Highlights Healthcare segment Specialty Chemicals segment • Total revenue of Rs. 2,358 million (vs. Rs. • Total revenue of Rs. 958 million up 8.1% y-o-y; 2,779 million in Q1 FY2015); EBIT margin of EBIT margin of 18.2% 14.9% (vs. 8.5%) • Margins improved significantly vs. Q4 FY2014 • This de
Slide 9: Segment Highlights
Segment Highlights Q1 y-o-y Q4 q-o-q Full Year y-o-y (Rs. million) FY2016 FY2015 Growth (%) FY2015 Growth (%) FY2015 FY2014 Growth (%) Segment Revenue 3,315 3,665 (9.6)% 3,562 (6.9)% 13,801 13,508 2.2% Specialty chemicals 958 886 8.1% 1,497 (36.0)% 4,462 4,143 7.7% Healthcare 2,358 2,779 (15.2)% 2,0
Slide 10: Quarterly Financial Trends
Quarterly Financial Trends Net Sales EBITDA and Margins 3,678 3,567 3,447 672 3,330 3,168 603 Rs. Million 581 Rs. Million 518 526 20.2% 16.3% 17.5% 15.8% 14.8% Q1 FY15 Q2 FY15 Q3 FY15 Q4 FY15 Q1 FY16 Q1 FY15 Q2 FY15 Q3 FY15 Q4 FY15 Q1 FY16 EBITDA Margin (%) Net Profit and Margins 242 206 Rs. Million
Slide 11: Capital Markets
Capital Markets Shareholding Structure Key Institutional Investors 35.3% 37.0% 1.6% 26.1% Promoters FII DII Others Shareholding Pattern Trend Shareholders Jun-14 Sep-14 Dec-14 Mar-15 Jun-15 Promoters1 38.1% 38.1% 38.1% 37.9% 37.0% FII / FDI 27.6% 27.7% 27.7% 27.7% 26.1% DII 2.3% 0.3% 0.1% 0.2% 1.6%
Slide 12: Strategic Direction
Strategic Direction Continue to strengthen engagements with marquee customer base through superior product development and delivery capabilities Where Chemistry and Quality Matters Move up the value chain through vertical integration in Healthcare (R&D to manufacturing of API / FDF / brands) and tar
Slide 13: Global Reach
Global Reach A multinational global platform that provides Vivimed access to markets and significant cost advantage Kashipur, Uttarakhand Haridwar, Uttarakhand Sant Celoni, Spain Lliçà de Vall, Spain Kolkata Cuernavaca, Mexico Bonthapally, Hyderabad Bidar, Karnataka Bolarum, Hyderabad Jeedimetla, Hy
Slide 14: Strong Transnational Management Team
Strong Transnational Management Team Key Management Profile Dr. V Manohar Rao • Retired as joint director of The Veterinary Biological and Research Institute and has over 40 years of Chairman industry experience • Responsible for developing a sophisticated and well-equipped in-house quality control
Slide 15: Annexure – Quarterly Consolidated P&L Statement
Annexure – Quarterly Consolidated P&L Statement Profit & Loss Statement (Rs. million) Q1 FY15 Q2 FY15 Q3 FY15 Q4 FY15 Q1 FY16 Revenues Net Sales / Income from Operations (Net of Excise Duty) 3,665 3,136 3,437 3,562 3,315 Other Operating Income 12 32 10 5 14 Total Revenues 3,678 3,168 3,447 3,567 3,3
Slide 16: Annexure – Consolidated Segment Performance
Annexure – Consolidated Segment Performance Q1 y-o-y Q4 q-o-q Full Year y-o-y (Rs. million) FY2016 FY2015 Growth (%) FY2015 Growth (%) FY2015 FY2014 Growth (%) Segment Revenue 3,315 3,665 (9.6)% 3,562 (6.9)% 13,801 13,508 2.2% Specialty chemicals 958 886 8.1% 1,497 (36.0)% 4,462 4,143 7.7% Healthcar
Slide 17: Glossary
Glossary • ANDA: Abbreviated New Drug Application • API: Active Pharmaceutical Ingredients • CEP: Certificates of Suitability to the monographs of European Pharmacopoeia • CMO: Contract Manufacturing Organization • DMF: Drug Master File • FDF: Finished Dosage Formulation • H&PC: Home and Personal Ca
Slide 18: Thank You
Thank You Contact Details: Vivimed Labs Limited (CIN: L02411KA1988PLC009465) Veernag Towers, Habsiguda, Hyderabad 500 007 www.vivimedlabs.com Phone: +91 40 2717 6005 / 06 Fax: +91 40 2715 0599 Ajay Mogili +91 40 2717 6005 Vivimed Labs Limited Ajay.Mogili@vivimedlabs.com Saket Somani +91 22 3953 7444